Recently, tocilizumab, a monoclonal antibody drug targeting IL-6, has been shown to have therapeutic potential for the treatment of COVID-19,68 which also highlights the vital role of anti-inflammatory response in current therapeutics against SARS-CoV-2. The gene discussed is IL6; the disease is COVID-19.